NDAINTRAVENOUSPOWDER
Approved
Jan 2022
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
5/8 — Partial
DAPZURA RT (daptomycin in sodium chloride) by Baxter is 12. Approved for pneumonia, left-sided infective endocarditis due to s, complicated skin and 16 more indications. First approved in 2022.
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DAPZURA RT is a ready-to-use intravenous formulation of daptomycin in sodium chloride, a lipopeptide antibacterial agent approved in January 2022. It treats complicated skin and skin structure infections (cSSSI), S. aureus bacteremia (including endocarditis), and pneumonia caused by susceptible gram-positive bacteria. Daptomycin works by disrupting bacterial cell membrane integrity, with efficacy correlating to AUC/MIC ratios.
Peak14.8 years to LOE
Product is in peak commercial lifecycle with stable market position; team size likely moderate to large for hospital/acute care focus.
Mechanism of Action
12.1 Mechanism of Action Daptomycin is an antibacterial drug [see ] . 12.2 Pharmacodynamics Based on animal models of infection, the antimicrobial activity of daptomycin appears to correlate with the AUC/MIC (area under the concentration-time curve/minimum inhibitory concentration) ratio for…
Worked on DAPZURA RT at Baxter? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.